

## Enablex (darifenacin) Prior Authorization Request Form Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640



**Instructions:** Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

	URGENT
MEMBER INFORMATION	
LAST NAME:	FIRST NAME:
PHONE NUMBER:	DATE OF BIRTH:
STREET ADDRESS:	
CITY:	STATE: ZIP CODE:
PATIENT INSURANCE ID NUMBER:	
MALE FEMALE HEIGHT (IN/CM): WEIG	HT (LB/KG): ALLERGIES:

IF YOU ARE NOT THE PATIENT OR THE PRESCRIBER, YOU WILL NEED TO SUBMIT A PHI DISCLOSURE AUTHORIZATION FORM WITH THIS REQUEST WHICH CAN BE FOUND AT THE FOLLOWING LINK: <u>https://magellanrx.com/member/external/commercial/common/doc/en-us/phi\_disclosure\_authorization.pdf</u>

## PATIENT'S AUTHORIZED REPRESENTATIVE (IF APPLICABLE): \_\_\_\_\_\_AUTHORIZED REPRESENTATIVE'S PHONE NUMBER: \_\_\_\_\_\_

PRESCRIBER INFORMATION			
LAST NAME:	FIRST NAME:		
PRESCRIBER SPECIALTY:	EMAIL ADDRESS:		
NPI NUMBER:	DEA NUMBER:		
PHONE NUMBER:	FAX NUMBER:		
STREET ADDRESS:			
CITY:	STATE: ZIP CODE:		
<b>REQUESTOR</b> (if different than prescriber):	OFFICE CONTACT PERSON:		

MEDICATION OR MEDICAL DISPENSING INFORMATION					
MEDICATION NAME:					
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILLS:	QUANTITY:		
NEW THERAPY		IF RENEWAL: DATE THERAPY	INITIATED:		
DURATION OF THERAPY (SPECIFIC DATES):					

Continued on next page.

© 2017 – 2018, Magellan Health, Inc. All Rights Reserved. Magellan Rx Management – Commercial Clients. Revision Date: 08/22/2018 CAT0295







MEMBER'S LAST NAME:	MEMBER'S FIRST NAME:			
1 HAS THE PATIENT TRIED ANY OTHER	R MEDICATIONS FOR THIS CONDITION?	YES (if yes, complete below) NO		
MEDICATION/THERAPY (SPECIFY	DURATION OF THERAPY (SPECIFY	RESPONSE/REASON FOR		
DRUG NAME AND DOSAGE):	DATES):	FAILURE/ALLERGY:		
2. LIST DIAGNOSES:		ICD-10:		
Overactive Bladder				
□ Other diagnosis:ICD-10				
<b>3. REQUIRED CLINICAL INFORMATION:</b> PRIOR AUTHORIZATION.	PLEASE PROVIDE ALL RELEVANT CLINIC	AL INFORMATION TO SUPPORT A		
Clinical Information:				
	th generic oxybutyninIR/ER, tolterodine	elR/ER, or trospiumIR/ER? □Yes □No		
Please submit documentation of dates of t	trial.			
Does the nationt have a contraindicati	on that precludes the use of oxybutynir	n tolterodine or trosnium? ⊐Ves ⊐No		
Please submit documentation.	on that preclades the use of oxybutynin			
Are there any other comments, diagno	oses, symptoms, medications tried or fai	iled, and/or any other information the		
physician feels is important to this rev	iew?			
*Disess notes Nist all dwigs /disensess				
information is received.	are covered on all plans. This request ma	y be defiled unless all required		
<b>ATTESTATION:</b> I attest the information provided is true and accurate to the best of my knowledge. I understand that				
	o or its designees may perform a routine	•		
information necessary to verify the accuracy of the information reported on this form.				
Prescriber Signature or Electronic I.D.	Verification:	Date:		
CONFIDENTIALITY NOTICE: The documents acco	ompanying this transmission contain confidential	health information that is legally privileged. If		
you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents				
of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX) and arrange for the return or destruction of these documents.				
FAX THIS FORM TO: 800-424-7640				
MAIL REQUESTS TO: Magellan Rx Management Prior Authorization Program; c/o Magellan Health, Inc. 4801 E. Washington Street, Phoenix, AZ 85034				
Phone: 877-228-7909				
	110101077 220 7505			

